JPRN-UMIN000037475已完成未知
Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer. - Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy (JCTB trial).
Japan cancer treatment and behavior study group(JCTB)0 个研究点目标入组 432 人开始时间: 2019年7月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 432
研究概览
简要总结
We failed to confirm that HLA B40 and B51 antigens significantly associated with response to PSK therapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Double cancer. 2. Prior cytotoxic or radiation therapy. 3. Abnormal bone marrow, hepatic and renal function 4. Severe cardiac, hepatic and lung failure, and an attending doctor was considered unsuitable.
研究者
相似试验
已完成
3 期
Human Papilloma Virus (HPV) Vaccination in Special Risk GroupsSpecial Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5. Chronic Renal Disease6. Bone Marrow TranssplantThe response to the HPV vaccine will be studied within these 6 special risk groups.Special Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5. Chronic Renal Disease6. Bone Marrow TranssplantThe response to the HPV vaccine will be studied within these 6 special risk groups.Inflammatory and Immune System - Other inflammatory or immune system disordersACTRN12609000571279ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation100
已完成
2 期
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South AfricaInfections, RotavirusNCT00263666GlaxoSmithKline100
已完成
3 期
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)InfluenzaNCT01204671GlaxoSmithKline4,659
Unknown
3 期
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCsImmunogenicitySafetyEfficacyNCT05686161Stemirna Therapeutics600
进行中（未招募）
不适用
A study to compare the immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed 1-dose Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infants.Infections, PneumococcalEUCTR2014-000750-11-Outside-EU/EEAGlaxoSmithKline Biologicals320